0

Human Vaccine Market by Route of Administration and Geography - Forecast and Analysis 2022-2026

  • Published: May 2022
  • Pages: 141
  • SKU: IRTNTR70325
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

According to Technavio's analyst, the human vaccine market size is expected to be valued at USD 20.37 billion by 2026 at a progressing CAGR of 7.73%. One of the key highlights of the human vaccine market research report is the post COVID-19 impact analysis on the market, which will help companies evaluate their business approaches for the forecast period. The human vaccine market report offers information on several market vendors, including Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd. among others. Furthermore, the human vaccine market has been broadly categorized into the following demographic segmentations: 

  • Route of administration - Intramuscular, subcutaneous, oral, and others
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Human Vaccine Market Size be During the Forecast Period?

Human Vaccine Market Size

Download the Free Report Sample to Unlock the Human Vaccine Market Size for the Forecast Period and Other Important Statistics

 

Human Vaccine Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The increase in investments in the vaccines segment is notably driving the human vaccine market growth, although factors such as concerns about the safety of vaccines may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the human vaccine industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Human Vaccine Market Driver

  • The increase in investments in the vaccines segment is one of the key drivers fueling the human vaccine market growth.
  • Companies across the world are increasingly investing in new vaccine development.
  • For instance, in November 2020, CEPI received a grant of up to $20 million from the Bill and Melinda Gates Foundation to expand its portfolio of COVID-19 vaccines to include candidates that are different from those already in the advanced development stage.
  • In December 2020, China's Sinovac Biotech announced that it had secured approximately $500 million in funding for the development of its COVID-19 vaccine. In 2021, the United States International Development Finance Corporation (DFC) invested $2.3 billion in India for the development of vaccines.

Such increasing investments will drive the human vaccine market growth during the forecast period.

Key Human Vaccine Market Trend

  • Varied demand for vaccines in high-income and developing countries is one of the key human vaccine market trends contributing to the market growth.
  • The demand for novel vaccines is high in developing countries, which receive financial support. In addition, the willingness to pay for immunization may be less in countries without funding or proper reimbursements for vaccinations.
  • Manufacturers in developing countries face challenges, such as high R&D costs and difficulty in conducting large placebo-controlled trials, where infection rates in vaccinated people may be compared with rates in the placebo-controlled group.
  • Vaccine industry associations, such as the Developing Countries Vaccines Manufacturers Network (DCVMN), serve as platforms to encourage the development of novel vaccines. This, in turn, will drive the human vaccine market growth during the forecast period.

Key Human Vaccine Market Challenge

  • Concerns about the safety of vaccines is one of the factors hindering the human vaccine market growth.
  • Vaccination product leaflets may list a few side effects which may be noticed in the controlled group.
  • For instance, the dengue vaccine has serious effects, including the occurrence of severe hemorrhagic dengue fever.
  • The concerns about the safety of vaccines in young children are increasing because they are less likely to be exposed to dengue before getting the dengue vaccine.
  • HPV vaccines have resulted in many safety issues, such as postural tachycardia syndrome and chronic fatigue syndrome. Thus, safety concerns about vaccines may hinder the growth of the global human vaccine market during the forecast period.

This human vaccine market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global human vaccine market as a part of the global pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the human vaccine market during the forecast period.

Who are the Major Human Vaccine Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bavarian Nordic AS
  • Bharat Biotech Ltd.
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Inovio Pharmaceuticals Inc.
  • Johnson and Johnson
  • Merck and Co. Inc.
  • Mitsubishi Chemical Holdings Corp.
  • Moderna Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.

 

This statistical study of the human vaccine market encompasses successful business strategies deployed by the key vendors. The human vaccine market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

  • Bavarian-nordic.com - The company offers ABNCoV2 which is a next-generation COVID-19 vaccine being developed as a universal booster to boost the immunity system among humans and to fight against variants of the SARS-CoV-2 virus.
  • Csl.com - The company offers cell-based seasonal influenza vaccine and next-generation self-amplifying mRNA for generating immune responses inside the body to fight against a particular disease.
  • Daiichisankyo.com - The company offers Human vaccine DS-5670 which is a mRNA developed in Japan have been evaluated against the novel coronavirus infectious disease.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The human vaccine market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Human Vaccine Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the human vaccine market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Human Vaccine Market?

Human Vaccine Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the human vaccine market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The increasing number of immunization programs and strong prevalence of infectious diseases will facilitate the human vaccine market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a positive impact on the regional market. However, by 2023, it is expected that a large proportion of the population will be vaccinated against COVID-19 in North America. Therefore, the market growth of the COVID-19 vaccine might decline in the region during the forecast period.

What are the Revenue-generating Route of Administration Segments in the Human Vaccine Market?

Human Vaccine Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The human vaccine market share growth by the intramuscular segment will be significant during the forecast period. The intramuscular segment is expected to witness accelerated growth during the forecast period. One of the main reasons for this growth is the benefits of intramuscular administration. It is efficient and safe in inducing an immune response compared with the oral ROA. Many pipeline vaccine products are being evaluated in the intramuscular ROA because of their advantages over the oral ROA. Thus, the market has witnessed the development and approval of an intramuscular vaccine for COVID-19, which is expected to drive the growth of the segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the human vaccine market size and actionable market insights on post COVID-19 impact on each segment.

 

Human Vaccine Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.73%

Market growth 2022-2026

$ 20.37 billion

Market structure

Fragmented

YoY growth (%)

5.3

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Human Vaccine Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive human vaccine market growth during the next five years
  • Precise estimation of the human vaccine market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the human vaccine industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of human vaccine market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
    • 3.4 Market outlook: Forecast for 2021-2026
      • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
      • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
      • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
    • 4.2 Bargaining power of buyers
      • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
    • 4.3 Bargaining power of suppliers
      • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
    • 4.4 Threat of new entrants
      • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
    • 4.5 Threat of substitutes
      • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
    • 4.6 Threat of rivalry
      • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
    • 4.7 Market condition
      • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

    5 Market Segmentation by Route of Administration

    • 5.1 Market segments
      • Exhibit 24: Chart on Route of Administration - Market share 2021-2026 (%)
      • Exhibit 25: Data Table on Route of Administration - Market share 2021-2026 (%)
    • 5.2 Comparison by Route of Administration
      • Exhibit 26: Chart on Comparison by Route of Administration
      • Exhibit 27: Data Table on Comparison by Route of Administration
    • 5.3 Intramuscular - Market size and forecast 2021-2026
      • Exhibit 28: Chart on Intramuscular - Market size and forecast 2021-2026 ($ million)
      • Exhibit 29: Data Table on Intramuscular - Market size and forecast 2021-2026 ($ million)
      • Exhibit 30: Chart on Intramuscular - Year-over-year growth 2021-2026 (%)
      • Exhibit 31: Data Table on Intramuscular - Year-over-year growth 2021-2026 (%)
    • 5.4 Subcutaneous - Market size and forecast 2021-2026
      • Exhibit 32: Chart on Subcutaneous - Market size and forecast 2021-2026 ($ million)
      • Exhibit 33: Data Table on Subcutaneous - Market size and forecast 2021-2026 ($ million)
      • Exhibit 34: Chart on Subcutaneous - Year-over-year growth 2021-2026 (%)
      • Exhibit 35: Data Table on Subcutaneous - Year-over-year growth 2021-2026 (%)
    • 5.5 Oral - Market size and forecast 2021-2026
      • Exhibit 36: Chart on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 37: Data Table on Oral - Market size and forecast 2021-2026 ($ million)
      • Exhibit 38: Chart on Oral - Year-over-year growth 2021-2026 (%)
      • Exhibit 39: Data Table on Oral - Year-over-year growth 2021-2026 (%)
    • 5.6 Others - Market size and forecast 2021-2026
      • Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
      • Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
      • Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)
    • 5.7 Market opportunity by Route of Administration
      • Exhibit 44: Market opportunity by Route of Administration ($ million)

    6 Customer Landscape

    • 6.1 Customer landscape overview
      • Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 46: Chart on Market share by geography 2021-2026 (%)
      • Exhibit 47: Data Table on Market share by geography 2021-2026 (%)
    • 7.2 Geographic comparison
      • Exhibit 48: Chart on Geographic comparison
      • Exhibit 49: Data Table on Geographic comparison
    • 7.3 North America - Market size and forecast 2021-2026
      • Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
      • Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
      • Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)
    • 7.4 Europe - Market size and forecast 2021-2026
      • Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
      • Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
      • Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)
    • 7.5 Asia - Market size and forecast 2021-2026
      • Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
      • Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
      • Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)
    • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
      • Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
      • Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
      • Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
    • 7.7 US - Market size and forecast 2021-2026
      • Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
      • Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
      • Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)
    • 7.8 Germany - Market size and forecast 2021-2026
      • Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
      • Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
      • Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)
    • 7.9 China - Market size and forecast 2021-2026
      • Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
      • Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
      • Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
    • 7.10 UK - Market size and forecast 2021-2026
      • Exhibit 78: Chart on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 79: Data Table on UK - Market size and forecast 2021-2026 ($ million)
      • Exhibit 80: Chart on UK - Year-over-year growth 2021-2026 (%)
      • Exhibit 81: Data Table on UK - Year-over-year growth 2021-2026 (%)
    • 7.11 Canada - Market size and forecast 2021-2026
      • Exhibit 82: Chart on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 83: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
      • Exhibit 84: Chart on Canada - Year-over-year growth 2021-2026 (%)
      • Exhibit 85: Data Table on Canada - Year-over-year growth 2021-2026 (%)
    • 7.12 Market opportunity by geography
      • Exhibit 86: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • 8.3 Impact of drivers and challenges
          • Exhibit 87: Impact of drivers and challenges in 2021 and 2026
        • 8.4 Market trends

          9 Vendor Landscape

          • 9.1 Overview
            • 9.2 Vendor landscape
              • Exhibit 88: Overview on Criticality of inputs and Factors of differentiation
            • 9.3 Landscape disruption
              • Exhibit 89: Overview on factors of disruption
            • 9.4 Industry risks
              • Exhibit 90: Impact of key risks on business

            10 Vendor Analysis

            • 10.1 Vendors covered
              • Exhibit 91: Vendors covered
            • 10.2 Market positioning of vendors
              • Exhibit 92: Matrix on vendor position and classification
            • 10.3 Bavarian Nordic AS
              • Exhibit 93: Bavarian Nordic AS - Overview
              • Exhibit 94: Bavarian Nordic AS - Product / Service
              • Exhibit 95: Bavarian Nordic AS - Key news
              • Exhibit 96: Bavarian Nordic AS - Key offerings
            • 10.4 CSL Ltd.
              • Exhibit 97: CSL Ltd. - Overview
              • Exhibit 98: CSL Ltd. - Business segments
              • Exhibit 99: CSL Ltd. - Key news
              • Exhibit 100: CSL Ltd. - Key offerings
              • Exhibit 101: CSL Ltd. - Segment focus
            • 10.5 Daiichi Sankyo Co. Ltd.
              • Exhibit 102: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 103: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 104: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 105: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 106: Daiichi Sankyo Co. Ltd. - Segment focus
            • 10.6 GlaxoSmithKline Plc
              • Exhibit 107: GlaxoSmithKline Plc - Overview
              • Exhibit 108: GlaxoSmithKline Plc - Business segments
              • Exhibit 109: GlaxoSmithKline Plc - Key news
              • Exhibit 110: GlaxoSmithKline Plc - Key offerings
              • Exhibit 111: GlaxoSmithKline Plc - Segment focus
            • 10.7 Inovio Pharmaceuticals Inc.
              • Exhibit 112: Inovio Pharmaceuticals Inc. - Overview
              • Exhibit 113: Inovio Pharmaceuticals Inc. - Product / Service
              • Exhibit 114: Inovio Pharmaceuticals Inc. - Key offerings
            • 10.8 Merck and Co. Inc.
              • Exhibit 115: Merck and Co. Inc. - Overview
              • Exhibit 116: Merck and Co. Inc. - Business segments
              • Exhibit 117: Merck and Co. Inc. - Key news
              • Exhibit 118: Merck and Co. Inc. - Key offerings
              • Exhibit 119: Merck and Co. Inc. - Segment focus
            • 10.9 Mitsubishi Chemical Holdings Corp.
              • Exhibit 120: Mitsubishi Chemical Holdings Corp. - Overview
              • Exhibit 121: Mitsubishi Chemical Holdings Corp. - Business segments
              • Exhibit 122: Mitsubishi Chemical Holdings Corp. - Key offerings
              • Exhibit 123: Mitsubishi Chemical Holdings Corp. - Segment focus
            • 10.10 Pfizer Inc.
              • Exhibit 124: Pfizer Inc. - Overview
              • Exhibit 125: Pfizer Inc. - Product / Service
              • Exhibit 126: Pfizer Inc. - Key news
              • Exhibit 127: Pfizer Inc. - Key offerings
            • 10.11 Sanofi
              • Exhibit 128: Sanofi - Overview
              • Exhibit 129: Sanofi - Business segments
              • Exhibit 130: Sanofi - Key news
              • Exhibit 131: Sanofi - Key offerings
              • Exhibit 132: Sanofi - Segment focus
            • 10.12 Serum Institute of India Pvt. Ltd.
              • Exhibit 133: Serum Institute of India Pvt. Ltd. - Overview
              • Exhibit 134: Serum Institute of India Pvt. Ltd. - Product / Service
              • Exhibit 135: Serum Institute of India Pvt. Ltd. - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Inclusions and exclusions checklist
                • Exhibit 136: Inclusions checklist
                • Exhibit 137: Exclusions checklist
              • 11.3 Currency conversion rates for US$
                • Exhibit 138: Currency conversion rates for US$
              • 11.4 Research methodology
                • Exhibit 139: Research methodology
                • Exhibit 140: Validation techniques employed for market sizing
                • Exhibit 141: Information sources
              • 11.5 List of abbreviations
                • Exhibit 142: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Human Vaccine market growth will increase by $20379.82 million during 2022-2026.
              The human vaccine market is expected to grow at a CAGR of 7.73% during 2022-2026.
              Technavio has segmented the human vaccine market by route of administration (Intramuscular, Subcutaneous, Oral, and Others) and geographic (North America, Europe, Asia, and Rest of World (ROW)).
              Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioNTech SE, CanSino Biologics Inc., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GlaxoSmithKline Plc, Gradalis Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Chemical Holdings Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd. are a few of the key vendors in the human vaccine market.
              North America will register the highest growth rate of 38.16% among the other regions. Therefore, the human vaccine market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the human vaccine market growth are:
              • Increase in investments in vaccines segment
              • Varied demand for vaccines in high-income and developing countries
              The human vaccine market vendors should focus on grabbing business opportunities from the intramuscular segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>